Get the Stockscreener App
0.095
9.09%
-0.0095
Aspire Biopharma Holdings Inc stock is traded at $0.095, with a volume of 35.22M.
It is down -9.09% in the last 24 hours and down -11.46% over the past month.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
See More
Previous Close:
$0.1045
Open:
$0.105
24h Volume:
35.22M
Relative Volume:
1.01
Market Cap:
$13.15M
Revenue:
-
Net Income/Loss:
$-27.39M
P/E Ratio:
-0.0565
EPS:
-1.6803
Net Cash Flow:
$-2.09M
1W Performance:
+3.83%
1M Performance:
-11.46%
6M Performance:
-75.00%
1Y Performance:
+0.00%
1-Day Range:
$0.092
$0.1144
1-Week Range:
$0.0709
$0.1144
52-Week Range:
$0.0709
$2.10
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Name
Aspire Biopharma Holdings Inc
Sector
Industry
Phone
561-704-8527
Address
23150 FASHION DRIVE, SUITE 232, ESTERO
Compare ASBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
0.095 | 14.47M | 0 | -27.39M | -2.09M | -1.6803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aspire Biopharma Holdings Inc Stock (ASBP) Latest News
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - Tallahassee Democrat
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance With Continued Listing Requirements - 富途牛牛
Aspire Biopharma gets Nasdaq extension to meet listing requirements By Investing.com - Investing.com Nigeria
POWP ACQUPAR : Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - marketscreener.com
Aspire Biopharma (Nasdaq: ASBP) gains extension, moves to Nasdaq Capital Market - Stock Titan
Aspire Biopharma Provides Q3 2025 Business Update - The Herald-Mail
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - Pensacola News Journal
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin - Victorville Daily Press
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - Alliance Review
Aspire Biopharma advances sublingual drug delivery technology By Investing.com - Investing.com Nigeria
Aspire Biopharma advances sublingual drug delivery technology - Investing.com
Aspire Biopharma (Nasdaq: ASBP) targets H1 2026 NDA after fast-acting aspirin data - Stock Titan
Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - Montgomery Advertiser
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Aspire Biopharma (NASDAQ: ASBP) Requests FDA Pre-IND Meeting on Sublingual AMI Aspirin - Stock Titan
ASBPWAspire Biopharma Holdings Inc Latest Stock News & Market Updates - Stock Titan
ASBPAspire Biopharma Holdings Inc Latest Stock News & Market Updates - Stock Titan
Aspire Biopharma adds pioneering drug delivery expert to scientific team By Investing.com - Investing.com Nigeria
Aspire Biopharma Holdings Inc Stock (ASBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):